Susanna Gatti High Sells 10,163 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 10,163 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at $5,256,821.36. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.01, for a total transaction of $1,042,842.87.
• On Wednesday, June 12th, Susanna Gatti High sold 40,000 shares of Dyne Therapeutics stock. The shares were sold at an average price of $33.36, for a total transaction of $1,334,400.00.
• On Monday, June 10th, Susanna Gatti High sold 80,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $30.24, for a total transaction of $2,419,200.00.
• On Thursday, May 16th, Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26.

Dyne Therapeutics Stock Up 0.0 %

Shares of NASDAQ DYN opened at $33.92 on Thursday. The firm has a 50-day simple moving average of $29.56 and a 200-day simple moving average of $24.26. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -8.54 and a beta of 1.06. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $36.60.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, meeting analysts’ consensus estimates of ($0.81). As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the business. DekaBank Deutsche Girozentrale increased its position in Dyne Therapeutics by 50.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the company’s stock worth $1,710,000 after purchasing an additional 20,000 shares during the last quarter. RA Capital Management L.P. acquired a new stake in Dyne Therapeutics during the first quarter worth about $140,666,000. Artal Group S.A. increased its position in Dyne Therapeutics by 24.6% during the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares during the last quarter. California State Teachers Retirement System increased its position in Dyne Therapeutics by 29.9% during the first quarter. California State Teachers Retirement System now owns 44,784 shares of the company’s stock worth $1,271,000 after purchasing an additional 10,317 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DYN has been the topic of a number of recent analyst reports. Chardan Capital increased their price target on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st. Piper Sandler increased their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. HC Wainwright increased their price objective on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a report on Monday, May 20th. Finally, Jefferies Financial Group increased their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, May 20th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.78.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.